Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002914086 | SCV003259215 | likely benign | Alagille syndrome due to a JAG1 point mutation | 2022-08-07 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004066257 | SCV003742083 | uncertain significance | Cardiovascular phenotype | 2023-10-08 | criteria provided, single submitter | clinical testing | The p.T169M variant (also known as c.506C>T), located in coding exon 4 of the JAG1 gene, results from a C to T substitution at nucleotide position 506. The threonine at codon 169 is replaced by methionine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Prevention |
RCV004548405 | SCV004795664 | uncertain significance | JAG1-related disorder | 2024-02-15 | no assertion criteria provided | clinical testing | The JAG1 c.506C>T variant is predicted to result in the amino acid substitution p.Thr169Met. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0054% of alleles in individuals of East Asian descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |